Objective To determine if topical ophthalmic diclofenac sodium 0.1% solution alters renal parameters in the domestic chicken, and to determine if the drug is detectable in plasma after topical ophthalmic administration. Animals Thirty healthy domestic chickens. Procedures Over 7 days, six birds were treated unilaterally with one drop of artificial tear solution (group 1), 12 birds were treated unilaterally (group 2) and 12 bilaterally (group 3) with diclofenac sodium 0.1% ophthalmic solution. Treatments were provided every 12 h in all groups. Pre-and post-treatment plasma samples from all birds were evaluated for changes in albumin, total protein, and uric acid. Post-treatment samples of all birds, collected 15 min post-administration, were analyzed by highperformance liquid chromatography with mass spectrometry for diclofenac sodium detection. A randomly selected renal sample from each group was submitted for histopathologic review. Results Changes in pre-and post-treatment plasma albumin were significant (P < 0.05) in groups 2 and 3, but not for group 1. Pre-and post-treatment changes in total protein and uric acid were not significant for any group. Diclofenac sodium was not detectable (limit of detection = 0.10 ng/mL) in plasma samples from birds in group 1. Post-treatment concentration of diclofenac in group 3 was statistically greater than group 2 (P = 0.0008). Histopathologic changes did not identify diclofenac-induced acute renal tubular necrosis. Conclusions Ophthalmic diclofenac sodium 0.1% administered topically every 12 h in one or both eyes for 7 days is detectable in systemic circulation in the domestic chicken, but does not cause overt significant changes in plasma uric acid or total protein.
INTRODUCTION
Diclofenac sodium 0.1% ophthalmic solution is a commercially available nonsteroidal anti-inflammatory drug (NSAID) used to treat inflammation associated with ocular disease by inhibiting cyclooxygenase, the enzyme responsible for prostaglandin synthesis during uveitis. 1, 2 Corticosteroids may also be used to treat ocular inflammation, however, topical corticosteroids are used cautiously in ophthalmic diseases due to potential side effects. 3 In birds, topical ophthalmic corticosteroids use is further limited by systemic absorption and consequent potential immunosuppression. 4 Side effects of topical ophthalmic NSAID therapy can include delayed wound healing, keratitis, and keratomalacia, but are generally more benign than effects of corticosteroids. [5] [6] [7] [8] [9] [10] Thus, topical NSAIDs are often preferred for chronic management of ocular inflammation in birds.
Recently, the use of diclofenac in some avian species has been investigated. Multiple studies have evaluated the toxic effects of oral and injectable diclofenac in various avian species following a sharp decline in the population of Gyps vultures in South Asia after the scavenger birds ingested carrion from diclofenac-treated livestock. These studies reported fatal renal disease and secondary visceral gout formation in the affected birds. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Topical diclofenac sodium ophthalmic solution has been used in domestic and wild-caught birds for treatment of ocular inflammation without reported negative clinical side effects. 21, 22 However, following topical ophthalmic application, medications are absorbed into systemic circulation, creating the potential for systemic side effects. 3, 23, 24 To the authors' knowledge, no studies have evaluated the bioavailability or hemodynamics of the drug following topical ophthalmic administration in avian species.
The purpose of this study is to determine if topical ophthalmic diclofenac sodium 0.1% solution adversely affects renal function in the domestic chicken, and to determine if the drug is detectable in plasma after topical ophthalmic administration. The authors hypothesized that a minor amount of diclofenac would reach detectable levels in plasma, but would not cause a significant change in the parameters used to monitor avian renal function.
MATERIALS A ND ME THODS
Approval for this study was obtained from the Iowa State University Institutional Animal Care and Use Committee. The study was conducted in accordance with the Association for Research in Vision and Ophthalmology guidelines concerning the use of animals in ophthalmic and vision research.
Thirty female domestic chickens (Gallus gallus domesticus) approximately 2 years of age with a mean weight of 1.46 AE 0.21 kg were acquired from a single laying farm. A single examiner (RA) performed a brief ophthalmic slitlamp biomicroscopy examination using a SL-15 (Kowa SL-15, Kowa, Tokyo, Japan). The wing tag number for each bird was recorded prior to being randomly assigned a study number . The flock was allowed 48 h to acclimate to the study environment.
On day 0, all birds were manually restrained for venipuncture of either the jugular or wing vein using a 25 gauge needle and 2.5 mL of whole blood was collected into a sodium heparin tube. Plasma was collected from the tubes after centrifugation (3300 rpm 9 10 min). Each plasma sample was divided evenly into two additive-free 1.5 mL blood collection tubes. The samples were kept at À80°C until analysis.
The animals were treated every 12 h with either artificial tear solution (Rubgy Laboratories, Livonia, MI, USA) (control) or diclofenac sodium 0.1% ophthalmic solution (Akorn Inc. Lake Forest, IL, USA) for 7 days. Group 1 (n = 6) received one drop of artificial tear solution in the left eye, group 2 (n = 12) received one drop of diclofenac sodium 0.1% in the left eye, and group 3 (n = 12) received one drop of diclofenac sodium 0.1% in both eyes. Throughout the study, each group was housed in a 1.2 9 2.4 m cage that was elevated 30.5 cm from the floor. The atmosphere was maintained at 21°C with a 12-h light:dark photoperiod. All groups received identical feed and water sources ad libitum.
At the end of the treatment period, an additional 2.5 mL of blood was collected, as previously described, 15 min after administration of the final treatment. Plasma was collected and stored via the previously described techniques. After venipuncture, the birds were immediately euthanized using 1-2 mL of intravenous pentobarbital sodium (390 mg/mL). Whole kidneys were harvested from each bird and fixed in 10% neutral-buffered formalin. One kidney from each treatment group was chosen randomly for histopathologic review. Tissue samples were sectioned into 5 lm cuts and stained with hematoxylin and eosin.
Biochemical analysis
Albumin, uric acid, and total protein levels for each bird from the frozen pre-and post-treatment plasma samples were determined with a commercial analyzer via the Iowa State University Lloyd Veterinary Medical Teaching Hospital clinical pathology laboratory within 72 h of collection.
Pharmacokinetic analysis
Detection of diclofenac concentration in the post-treatment plasma samples from each bird was performed approximately 75 days after collection using high-performance liquid chromatography with mass spectrometry as previously described. 25 Plasma proteins were precipitated by adding 400 lL of acetonitrile to 100 lL of plasma sample. Flufenamic acid was combined with the acetonitrile as an internal standard at a concentration of 200 ng/mL.
The injection volume was set to 20 lL and HPLC-MS analysis was performed as previously described. 25 Diclofenac and flufenamic acid eluted at 5.7 and 6.2 min, respectively.
Full scan mass spectrometry of the pseudomolecular ions of diclofenac (m/z 297) and flufenamic acid (m/z 282) was used for analyte detection. The sum of the intensities of ions at 215, 250, and 252 m/z was used for diclofenac quantification. The internal standard, flufenamic acid, was quantified with the sum of the fragment ion intensities at 196, 216, and 244 m/z. Eleven calibration spikes were prepared in blank chicken plasma covering the concentration range of 0.25 to 1000 ng/mL. Calibration curves exhibited a correlation coefficient (r 2 ) exceeding 0.993 across the concentration range. Quality control samples at 3, 30, and 300 ng/mL were within a tolerance of AE 15% of the nominal value. The limit of quantification of the analysis was 0.25 ng/mL with a limit of detection of 0.10 ng/mL.
Statistical analysis
Statistical analysis was performed using commercially available computer software (SAS Statistical Software 9.3; SAS Institute Inc, Cary, NC, USA). Due to nonparametric distribution, pre-and post-treatment biochemical parameters (albumin, uric acid, and total protein) within each group were compared using the Wilcoxon signed-rank test. P values <0.05 were considered significant.
Plasma diclofenac concentrations between groups 2 and 3 were compared using a one-way ANOVA.
RE SUL TS
Pre-and post-treatment albumin, uric acid, and total protein means for each group are summarized in Table 1 . Statistical analysis revealed no significant difference between pre-and post-treatment total protein or uric acid parameters within any group. A significant decrease in albumin levels was present in post-treatment groups 2 (P = 0.036) and 3 (P = 0.003) when compared to pretreatment values.
Post-treatment plasma diclofenac concentrations were undetectable in samples from each bird in group 1. Detectable concentrations of diclofenac were present in all animals from groups 2 and 3. Results are summarized in Fig. 1 . Bird #24 (group 3) was identified as an outlier, but it was not influential since drug concentrations in group 3 were significantly greater than group 2 with (P = 0.0008) and without (P = 0.0001) including this data point.
Histopathologic examination of the three kidneys (one from each group) showed similar changes. Each sample demonstrated hypercellular mesangial regions in one-third to half of the renal corpuscles within enlarged glomeruli. The peripheral capillary loops in the enlarged glomeruli were distended with a thickened basement membrane. Hypertrophied podocytes and occasional adhesions to Bowman's capsule were also present. These changes are consistent with chronic proliferative glomerulonephritis. The renal tubules maintained normal architecture.
DISCUSSION
Topical ophthalmic diclofenac administered twice daily to chickens unilaterally or bilaterally for 1 week resulted in detectable plasma levels of drug and minor biochemical alterations. Elevation in uric acid and decreases in albumin and total protein have been demonstrated in plasma of domestic chickens after administration of oral diclofenac sodium in a previous study. 11 For comparison, the present study evaluated for biochemical evidence of renal pathology by monitoring plasma albumin, total protein, and uric acid levels after administration of topical ophthalmic diclofenac sodium 0.1% for 1 week.
Significant decreases in post-treatment albumin were present within the groups treated with diclofenac (groups 2 and 3). A statistical difference was not detected for total protein or uric acid in any of the three groups. Uric acid is a more reliable indicator of avian renal pathology than albumin or total protein. 26 In the present study, although albumin decreased post-treatment, it was maintained within previously published reference intervals. 27 Various disease processes decrease albumin while increasing globulin. 28 This potentially results in the cumulative total protein remaining within a normal reference interval. The use of albumin:globulin ratio has more clinical significance. 29 Therefore, the resultant change in albumin in the present study may or may not reflect changes in renal function.
In birds, 90% of uric acid is eliminated via the kidneys and is used in conjunction with clinical signs and other *Denotes a significant difference from pre-treatment value (P < 0.05). Group 1 = control group receiving artificial tear solution on the left eye twice daily. Group 2 = treatment group receiving diclofenac sodium 0.1% on the left eye twice daily. Group 3 = treatment group receiving diclofenac sodium 0.1% on both eyes twice daily. diagnostic testing to assess renal disease. 30 In group 3 of the present study, although there was not a significant change in uric acid before and after treatment, this variable increased outside the reference interval. Fluctuations in uric acid are possible due to extrarenal causes and other confounding factors (species, diet, age, environment, ovulatory activity, and laboratory methodology for sample processing), therefore sequential evaluation is preferred to evaluate for renal dysfunction. 30, 31 Ultimately, single-point biochemical parameters may raise suspicion for renal pathology, but antemortem diagnosis is most accurately made when combining serial clinical pathologic abnormalities with clinical signs (lethargy, polyuria, weakness), urinalysis, abdominal imaging, and endoscopic renal evaluations. 32, 33 The significance of the increase in uric acid in group 3 of the present study is unknown.
Concentration of diclofenac in plasma was determined using high-performance liquid chromatography with mass spectrometry. Post-treatment samples were negative for diclofenac in control birds. In a review of ophthalmic medications, it was determined that approximately half of the topical drugs evaluated reached peak plasma concentration after 15 min of administration in humans. 23 Another study reported the time to maximum plasma concentration after ophthalmic administration of diclofenac sodium 0.1% was 15 min in rabbits. 34 Although the pharmacokinetic profile of topical ophthalmic diclofenac sodium 0.1% in birds has not been established, the timing of post-treatment sample collection in the current study was selected based on those previous reports. As expected, diclofenac was detected in group 2 (mean = 25.4 AE 9.19 ng/mL) and group 3 (mean = 51.3 AE 21.19 ng/mL), but not in group 1.
Biochemical or fatal changes of diclofenac-treated birds in previous studies occurred at doses ranging from 0.005 mg/kg to 20 mg/kg with Gyps vultures being the most sensitive to effects. 11, 12, 14, [16] [17] [18] [19] [20] Of the studies that utilized chickens, a 2 mg/kg dose caused biochemical, but nonlethal, changes. 11 If we assume 100% systemic absorption of the diclofenac sodium ophthalmic drops (~0.04 mg/drop), the mean per treatment dose of diclofenac for birds in the present study is approximately 0.028 mg/kg and 0.057 mg/kg for the treated groups 2 and 3, respectively. The extent of systemic absorption from topically applied ophthalmic diclofenac is unknown, however, given the low plasma concentration detected in the present and previous studies it is unlikely that a toxic level could be reached in plasma. 3, 35 Previous studies demonstrated that sensitivity differences in response to NSAIDs exist between avian species. [12] [13] [14] 18 For example, one report determined that although chickens can succumb to diclofenac toxicity (50% lethal dose~10 mg/kg), they are more tolerant of the biochemical effects (abnormal renal parameters and acute renal tubular necrosis) compared to Gyps vultures (50% lethal dose~0.1 mg/kg). 12, 14 Other studies reported the Pied crow (Corvus albus) and turkey vulture (Cathartes aura) were not susceptible to diclofenac-induced renal toxicity at the doses evaluated in those reports. 12, 18 Although the present study demonstrated the apparent safety of unilateral or bilateral twice daily ophthalmic diclofenac administration in chickens, it may not be possible to extrapolate the safety of this dose to all avian species.
Chronic proliferative glomerulonephritis was observed histopathologically in one randomly selected sample from each of the three treatment groups. These lesions differ from the glomeruli-sparing acute proximal convoluted tubular necrosis observed in Pakistani vultures (Gyps bengalensis) that were naturally and experimentally exposed to diclofenac via ingestion of contaminated meat. 16, 17 Acute renal tubular necrosis has been documented in a variety of other avian species after treatment with diclofenac sodium, including the domestic chicken. 11, 13, 14 Renal tubules maintained normal architecture in all histopathologic specimens in the present report. Due to the different region of the kidneys affected (glomeruli vs. tubules), and given the control group in the present study was also affected; it is unlikely the lesions were caused by diclofenac administration. Glomerulonephritis reportedly occurs spontaneously in clinically normal chickens, as well as in conjunction with numerous disease processes. [36] [37] [38] [39] [40] [41] [42] In general, there are many etiologic causes for avian renal disease, including viruses, bacteria, parasites, mycotoxins, neoplasia, and nutritional imbalances. 33, 43 Additional testing to attempt to diagnose the underlying cause of the chronic glomerulonephritis identified with histopathology was not performed in this study and was presumed to be preexisting. No birds exhibited clinical signs of disease throughout the duration of the present study, and visceral gout was not observed during postmortem examinations.
Limitations to the present study include a short duration and infrequency of treatment. When treating clinical disease, ophthalmic NSAID dosing may be required several times daily and several weeks of treatment may be necessary. 4 Increasing the frequency of treatment to four times daily in both eyes would likely result in increased systemic absorption of the medication, thereby increasing the risk of biochemical effects of the drug. Additionally, the exact time to peak plasma concentration of ophthalmic diclofenac sodium in chickens is unknown, therefore higher concentrations of drug may be present before or after the 15 min collection point used in the present study. Methodology of sample collection and processing must also be considered when interpreting results. As was used in the present study, many laboratories use the bromocresol green method to test albumin levels. This method, which uses human albumin for standards and controls, has not been validated for avian species. 44 Discrepancies between the bromocresol green method and gel electrophoresis indicate the latter is the preferred method for determination of avian albumin concentrations. 29, 45, 46 Financial limitations prohibited using gel electrophoresis in the present study. Urinalysis to assess renal function can be performed by patient catheterization or via collection from fresh droppings. 44, 47 These techniques require anesthesia or housing birds individually which was not feasible in this study. Additionally, financial constraints prohibited histopathologic evaluation of additional kidneys collected at necropsy. Finally, a small per group sample size may have led to the abnormally distributed data, which prohibited the comparison of biochemical parameters between groups.
Results of this study indicate diclofenac is detectable in systemic circulation in the domestic chicken at 15 min post-administration of ophthalmic diclofenac sodium 0.1% every 12 h in one or both eyes for 1 week. Although biochemical changes were detected, the lack of clinical evidence of renal pathology and lack of histopathologic acute tubular necrosis suggest that topical ophthalmic diclofenac sodium did not have negative renal effects in the present study. Due to the possibility of different interspecies response to NSAIDs, further investigation of topical ophthalmic diclofenac sodium effects on the more commonly treated domestic bird species (i.e., passerines and pscittacines) is warranted.
